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Patient factors influencing acute gluten
reactions and cytokine release in treated
coeliac disease
Jason A. Tye-Din1,2,3†, A. James M. Daveson4,5†, Kaela E. Goldstein6, Holly L. Hand6, Kristin M. Neff6, Gautam Goel6,
Leslie J. Williams6, Kenneth E. Truitt6, Robert P. Anderson6,7* and on behalf of the RESET CeD Study Group

Abstract
Background: Patients with coeliac disease (CD) commonly report a variety of adverse symptoms to gluten, but
descriptions of the symptomatic response in the literature may have been confounded by the presence of food
components such as fermentable carbohydrates (FODMAPs) causing symptoms of irritable bowel syndrome
independent of gluten. In recent unmasked and masked low FODMAP gluten challenge studies in small groups of
treated CD patients, nausea and vomiting were shown to be the key symptoms associated with serum interleukin
(IL)-2 release. Our objective was to utilise a large and diverse cohort of people with CD undertaking a standardised
gluten food challenge to characterise the demographic, genetic and clinical factors influencing the severity and
timing of acute gluten reactions and IL-2 production.
Methods: A total of 295 adults treated for CD were observed for 6 h after an unmasked food challenge consisting
of 10 g vital wheat gluten (low in FODMAPs) in 100 ml water. Assessments included patient-reported outcomes,
serum IL-2 and adverse events. Responses were analysed according to patient characteristics, HLA-DQ genotype,
duodenal histology and response to a second gluten challenge.
Results: Peak symptom severity was at 3 h (median severity 5/10). Peak IL-2 was at 4 h (median 4 pg/ml, range
undetectable to 1028 pg/ml). Older age, older age at diagnosis, HLA-DQ2.5 positivity and homozygosity for HLADQB1*02 were each significantly associated with IL-2 elevations after gluten. Patients positive for HLA-DQ2.5, DQ8,
DQ2.2 or DQ7 showed elevated IL-2 after gluten. Patient factors were not significantly associated with severity of
digestive symptoms, but symptoms were correlated to one another and serum IL-2. Gluten challenge after
5 months caused more vomiting and higher IL-2 levels, but responses correlated with the first.
Conclusions: Gluten-induced symptoms and cytokine release is common in adults with treated CD. Age, genetics
and previous response to gluten predict these acute reactions to gluten challenge. Structured symptom assessment
and serum IL-2 after standardised gluten challenge may inform on patient diagnosis, the role of gluten in
symptomatology and the need for adjunctive treatment.
Trial registration: ClinicalTrials.gov, NCT03644069 Registered 21 May 2018.
Keywords: Coeliac disease, Gluten, Food challenge, Cytokine, Patient-reported outcome

* Correspondence: banderson99133@gmail.com
†
Jason A. Tye-Din and A. James M. Daveson contributed equally to this work.
6
ImmusanT Inc., Cambridge, MA, USA
7
Wesley Medical Research, PO Box 499, Toowong, QLD 4066, Australia
Full list of author information is available at the end of the article
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.

Tye-Din et al. BMC Medicine

(2020) 18:362

Background
Coeliac disease (CD) is a prevalent, small intestinal
immune-mediated enteropathy precipitated by exposure to
dietary gluten in genetically predisposed people [1, 2]. Patients with CD commonly report adverse symptoms associated with gluten ingestion [3], but there are few studies
that rigorously control for confounding effects to enable
accurate gluten-related symptomatology to be recorded.
These include nocebo effects, where patient’s negative
expectations to potential gluten exposure influence their
symptoms and the presence of non-gluten dietary components such as fermentable carbohydrates (FODMAPs) that
can cause symptoms of irritable bowel syndrome (IBS) independent of gluten [4, 5]. In several recent gluten food
challenge studies in small groups of patients with treated
CD, unmasked and also double-blind, sham-controlled gluten challenges designed to be low in FODMAPs cause significant worsening of nausea, sometimes with vomiting,
within 2-h and peak at 3 to 4 h, but rarely caused diarrhoea
[6, 7]. This acute symptomatic reaction to gluten in patients with treated CD is linked to significant concomitant
elevations in serum cytokines, which are not observed in
individuals without CD or those with self-reported nonCD gluten sensitivity [7–9].
Serum levels of interleukin (IL)-2 increase earliest and
most in the serum cytokine signature observed after gluten
[10]. An almost identical set of digestive symptoms and systemic cytokine release occurs after patients with treated CD
receive an intradermal injection of gluten peptides corresponding to immuno-dominant HLA-DQ2.5-restricted epitopes for gluten-specific CD4+ T cells [8, 11]. Collectively,
these findings implicate an unexpected leading role for activated gluten-specific CD4+ T cells in the early symptoms
after gluten. However, more detailed understanding
requires studies in substantially larger cohorts that are not
focused on patients positive for HLA-DQ2.5 alone.
The objective of the present study was to characterise
demographic, genetic and clinical factors influencing the
severity of symptoms and IL-2 release after gluten in a
large cohort of patients having a standardised, low FODMAP gluten challenge. The data provide a roadmap outlining the potential clinical role for bolus gluten challenge

Fig. 1 Study outline
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in the care of patients with and without CD following a
gluten-free diet.

Methods
Study design

The study design is shown in Fig. 1. Here, we report data
collected from 295 CD individuals during the screening
(pre-treatment) phase of the “RESET CeD Study”, a phase
2 clinical trial of an investigational treatment for CD
(ClinicalTrials.gov identifier: NCT03644069). Full details
of the RESET CeD Study design are described elsewhere
[6]. There were 39 sites in the USA, Australia and New
Zealand. All participants undertook an unmasked (i.e.
open-label) gluten food challenge coupled with an assessment of IL-2 and symptom responses. A later component
of the RESET CeD Study following the administration of
the experimental drug/placebo involved CD participants
completing a double-blind food challenge of gluten at the
same dose and format as undertaken during screening or
a matched non-gluten placebo, each low in FODMAPs
and consumed 2 weeks apart. The data from the 36 CD
patients who received placebo drug helps control for
nocebo effects associated with open-label administration
of gluten and is reported elsewhere [6].
Participants and study procedures

All patients gave written, informed consent prior to
undergoing any trial-related procedures. Full eligibility
criteria are listed elsewhere [6]. To enter screening, patients’ ages were between 18 and 70 years, they had
documentary evidence of duodenal villous atrophy and
elevated CD-specific serology and had followed a glutenfree diet for at least 1 year. Patients were excluded from
the analysis if their HLA-DQ genotype was subsequently
found to be incompatible with CD (absence of HLADQA1*05, HLA-DQA1*03, HLA-DQB1*02 or HLADQB1*03), or no symptom data had been recorded after
screening gluten challenge. Unmasked gluten challenge
was as described by Tye-Din et al. [7]. The composition
was as described by Daveson et al. [6]. The food challenge, taken as a bolus in 100 ml water over 2 min, comprised 10 g vital wheat gluten (Gem of the West® Vital
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Wheat Gluten, Manildra Group, Auburn, NSW,
Australia). The protein content of the vital wheat gluten
was 78 g per 100 g (Eurofins Microbiology Laboratories
Inc). FODMAP content was low, with a total fructan of
0.074 g/serve and a total FODMAP of 0.089 g/serve
using reported methods [12] (Monash University, Melbourne, Victoria, Australia).
Clinical assessments

Demographics, medical history and prior and concomitant
medications were recorded. Patients completed the characteristics of CD survey described by Tye-Din et al. [7]
and the Celiac Dietary Adherence Test (CDAT) [13]. As
described elsewhere [7], self-reported symptom severity
was recorded within an hour before, and then each hour
up to 6 h after gluten challenge using a modified version
of the “Celiac Disease Patient-Reported Outcome” (CeD
PRO®) tool, and using a global gastrointestinal symptom
survey (GloSS). Adverse events during the 24 h after
gluten challenge were separately recorded and graded by
investigators according to Common Terminology Criteria
for Adverse Events, version 4.03.
Laboratory assessments

CD serology (QUANTA Lite® “R h-tTG IgA” and “gliadin IgG II (DGP)”, INOVA Diagnostics, San Diego, CA,
USA) was performed by ARUP (Salt Lake City, UT).
HLA-DQ genotype was evaluated by the UCLA Immunogenetics Center (Los Angeles, CA). The blood for IL-2
was allowed to clot for 30 min and, within 3 h, aliquots
of the serum were frozen and stored at − 60 to − 80 °C.
Serum IL-2 was measured by a commercial V-PLEX
electrochemiluminescence assay as previously described
[6]. The lower level of quantitation was 0.5 pg/ml.
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symptoms”) to the worst (“very severe symptoms”) was
deemed to be their worst recorded hourly GloSS descriptor
over the 6-h interval after gluten.

Results
Patient characteristics

In total, data for 295 patients who had gluten challenges
were analysed, which represented 77% of the 383 volunteers who were screened, and 95% of all the patients
who were eligible and had a screening gluten challenge
over the period from August 2018 to March 2019. Disposition of patients is shown in Additional file 1: Figure
S1. The gluten challenge was on the first day of screening for 214 patients, or between 1 and 31 days after
starting the screening for 96 patients. Demographics and
characteristics of patients are shown in Table 1.
Patient-reported outcomes after gluten challenge

There was a good agreement between verbal descriptor
and numerical score for peak hourly GloSS rating (Spearman r = 0.92, p < 10−15, n = 295) (Additional file 1: Table
S1). Table 2 shows the distribution of peak GloSS severity
and CeD PRO severity for individual symptoms. The overall severity of reactions based on peak GloSS descriptor
was moderate and rated 5 on a scale from 0 to 10. Gluten
reactions were graded moderate, severe or very severe by
almost two thirds of patients. Figure 2 shows the time
course for GloSS and CeD PRO ratings for global and individual symptoms, respectively. We again observed that patients’ expectations of symptoms were often not those
experienced after gluten challenge (Additional file 1: Tables
S2, S3) [6]. Onset was within 1 h, and peak overall severity
Table 1 Patient characteristics
Mean (SD) age in years

43 (15)

Statistical analyses

Number (%) of females

205 (69)

We utilised non-parametric tests as we did not assume a
normal distribution for the data. The Mann-Whitney test
was used to compare two datasets of continuous variables
that were unpaired, and for paired data, the Wilcoxon
signed rank test and Spearman’s coefficient of correlation
were used. Kruskal-Wallis testing was used to compare
groups of three or more continuous variables in the same
participant. Associations between categorical variables were
tested by the Fisher exact test, chi-square test or CochranArmitage test depending on whether two variables, more
than two variables or an order-dependent trend in variables
was present, respectively. All statistical tests were 2-tailed,
and a p value of 0.05 was taken as significant. BenjaminiHochberg’s false discovery rate method was used to adjust
p values for multiple comparisons where appropriate. Summary and significance statistics were computed using
Graphpad Prism V7.0d. The overall clinical severity of a
reaction to gluten for an individual from the least (“no

Mean (SD) height in centimetres

169 (11)

Mean (SD) body mass in kilogrammes

79 (19)

Mean (SD) body mass index

28 (13)

Number (%) of White, not Hispanic or Latino

277 (94)

Median (interquartile range) age in years at diagnosis of CD

35 (25–46)

Median (interquartile range) years from coeliac diagnosis

6 (3–10)

Number (%) of negative for both CD-specific serologies†

241 (82)

Number (%) of positive for both CD-specific serologies†

5 (2)

Number (%) of IgA deficient (< 7 mg/dl)

2 (1)

Number (%) of positive for HLA-DQ2.5 genotype

266 (90)

Number (%) of negative for HLA-DQ2.5 genotype

29 (10)

Number (%) of recruited in the USA

126 (43)

Number (%) of recruited in Australia

123 (42)

Number (%) of recruited in New Zealand

46 (16)

†

QUANTA Lite® R h-tTG IgA (normal range 3 U/ml or less) and gliadin IgG II
(DGP), INOVA Diagnostics (normal range 19 U or less)

Tye-Din et al. BMC Medicine

(2020) 18:362

Page 4 of 10

Table 2 Peak severity of symptoms up to 6 h after consuming gluten
Gluten reaction severity‡
Number of patients (%)

All

None

Very mild

Mild

Moderate

Severe

Very severe

8 (3)

33 (11)

65 (22)

104 (35)

54 (18)

31 (10)

295

†

Median peak hourly severity of digestive symptoms rated each hour in the Global Symptom Survey (interquartile range)
Absolute value

0 (0–0)

2 (1–2)

2 (1–2)

6 (5–6)

8 (8–8)

10 (9–10)

5 (3–8)

Change from baseline

0 (0–0)

1 (1–2)

1 (1–2)

5 (5–6)

8 (7–8)

10 (9–10)

5 (3–7)

Median peak hourly symptom score in modified CeD PRO† (interquartile range)
Nausea

0 (0–0)

1 (0–2)

2 (1–4)

5 (3–6)

8 (7–9)

10 (10–10)

4 (2–8)

Diarrhoea

0 (0–0)

0 (0–0)

0 (0–0)

0 (0–1)

1 (0–6)

8 (1–10)

0 (0–3)

Loose stool

0 (0–0)

0 (0–0)

0 (0–1)

0 (0–3)

2 (0–8)

8 (2–10)

0 (0–3)

Cramping

0 (0–1)

1 (0–1)

2 (1–3)

4 (2–5)

7 (4–8)

8 (6–9)

4 (1–6)

Pain

0 (0–1)

1 (0–1)

2 (1–3)

4 (3–5)

6 (5–8)

8 (6–9)

4 (1–6)

Tiredness

2 (0–3)

2 (1–3)

3 (2–5)

6 (4–7)

7 (7–8)

6 (5–8)

5 (3–7)

Bloating

0 (0–0)

2 (1–2)

3 (2–3)

5 (3–6)

7 (5–7)

5 (3–7)

4 (2–6)

Gas

0 (0–0)

1 (1–2)

2 (1–3)

3 (2–4)

4 (2–6)

4 (1–7)

2 (1–4)

Headache

0 (0–0)

1 (0–3)

2 (0–4)

4 (2–6)

3 (1–8)

2 (1–6)

3 (1–5)

‡

Peak overall severity was the worst hourly descriptor rating reported by patients over 6 h after gluten challenge in the Global Symptom Survey for the question,
“Overall, how would you rate the severity of your digestive symptoms in the past 1 h? (e.g. feeling or being sick, abdominal pain or cramps, feeling bloated,
having loose stools or passing gas)”
†
Whole number rating scale from 0 for no symptoms to 10 for worst possible symptoms

of moderate, severe and very severe reactions was clearly at
3 h. Nausea, cramping and abdominal pain, bloating and
tiredness steadily worsened as the overall severity of reactions increased, but diarrhoea and loose stool were only
prominent in very severe reactions. Additional file 1: Table
S4 shows that the peak severity of all individual symptoms
assessed by the CeD PRO was correlated with one another.
The strongest correlations were between the most prominent symptoms such as nausea, pain, cramping, bloating and
tiredness. Table 3 shows how often patients rated
individual symptoms among their three worst during the
6 h after gluten challenge. Nausea, tiredness and abdominal pain/cramping were each rated among the worst
symptoms for almost half of the patients, but nausea and
vomiting were clearly most often the worst symptoms for
patients having very severe reactions.

Adverse events after gluten challenge

The timing, prevalence, and severity of adverse events
were generally consistent with patient-reported outcomes (Additional file 1: Table S5). Vomiting affected
62 (21%) patients and was the only common adverse
event not among those included in the CeD PRO.
There were no serious adverse events, but 37 (13%)
patients experienced a severe adverse event. Nausea
and vomiting accounted for the majority of adverse
events graded severe. The timing of onset for adverse
events indicated a consistent march of symptoms
beginning with nausea.

Serum IL-2 after gluten challenge

Serum IL-2 significantly increased by 2 h and typically
peaked at 4 h (Fig. 3a). Altogether, serum IL-2 levels were
elevated at 4 h in 216 (73%) patients who had baseline
levels below 0.5 pg/ml. In addition, there were isolated
elevations of IL-2 at 2 h in seven patients and at 6 h in
four patients. Therefore, the total number of patients who
elevated serum IL-2 from baseline to levels above the
lower level of quantitation or at least 1.9 times more than
the baseline was 229 (78%).
The median peak serum IL-2 concentration was 4 pg/ml
(interquartile range 0.7–13), and the median peak fold
change from baseline was 7 (interquartile range 1.2–25).
The peak serum IL-2 levels were not normally distributed
(Fig. 3b). The highest peak serum IL-2 concentration observed was 1075 pg/ml. Two (1%) patients had peak IL-2
levels above 1000 pg/ml, 15 (5%) had peak IL-2 levels above
100 pg/ml and 73 (25%) had peak IL-2 levels above 10 pg/
ml, whereas serum IL-2 remained below 0.5 pg/ml in 63
(21%) patients. Serum IL-2 levels were above the lower level
of quantitation (0.5 pg/ml) at baseline in five (2%) patients.
Correlation between symptoms and IL-2 after gluten
challenge

The serum IL-2 concentration at 4 h was correlated most
strongly with peak GloSS score (Additional file 1: Table S4,
Fig. 3c), and serum IL-2 time profiles were elevated most
and for longer in very severe reactions (Fig. 3d). Nausea
was the symptom most correlated with peak serum IL-2
levels (Fig. 3e), but correlations were also found with the
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Fig. 2 Six-hour time series after gluten for patient-reported outcome scores (modified CeD PRO and Global Symptom Survey). Profiles are for all patients (a–c)
and for patients whose worst global gastrointestinal score over 6 h was “no symptoms” (d–f), “mild symptoms” (g–i), “very mild symptoms” (j–l), “moderate
symptoms” (m–o) and “severe symptoms” (p–r), “very severe symptoms” (s–u). Points indicate mean ± standard error of the mean for scores rated 0 to 10

severity of abdominal pain, abdominal cramping, bloating,
loose stool and diarrhoea (Additional file 1: Table S4). Patients who vomited after gluten had median serum IL-2
levels at 4 h that were ten times higher than other patients
(Fig. 3f). Among the 65 patients who did not show any elevation in serum IL-2, their peak GloSS severity was rated
very mild in 11 (17%), mild in 21 (31%), moderate in 27
(42%) and severe in 4 (6%). Comparing patients who had
no detectable elevation of IL-2 with patients who did, only
nausea (median 3 vs 5, p = 0.004), global symptoms

(median 4 vs 6, p = 0.0009) and vomiting (1 vs 60, p =
0.000024) were different. Interestingly, all eight patients
who reported no symptoms had elevations in serum IL-2
levels from below 0.5 pg/ml at baseline to between 0.8 and
6.9 pg/ml.
Associations between patient characteristics and gluten
reactions

Additional file 1: Table S6 lists patient characteristics
and their associations with peak global gastrointestinal

(2020) 18:362
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Table 3 Number (%) of participants reporting a symptom as among their three most troubling symptoms after gluten challenge
according to peak reaction severity
Peak severity of global gastrointestinal symptoms (GloSS)‡
Nonea

Totalb

Very milda

Milda

Moderatea

Severea

Very severea

Total patients

8 (3)

33 (11)

65 (22)

104 (35)

54 (18)

31 (11)

295 (100)

Nausea

1 (13)

5 (15)

29 (45)

54 (52)

32 (60)

21 (72)

142 (49)

Tiredness

3 (38)

16 (48)

32 (50)

50 (49)

24 (45)

3 (10)

128 (44)

Abdominal pain/cramps

1 (13)

8 (24)

24 (38)

48 (47)

24 (45)

13 (45)

118 (41)

Bloating

0

15 (45)

22 (52)

43 (42)

15 (28)

1 (3)

107 (37)

Headache

1 (13)

14 (42)

24 (38)

44 (43)

16 (30)

4 (14)

103 (36)

Vomiting

0

0

1 (2)

13 (13)

24 (45)

26 (90)

64 (22)

Gas

0

8 (24)

25 (39)

21 (20)

6 (11)

0

60 (21)

Diarrhoea/loose stool

0

1 (3)

5 (8)

12 (12)

11 (21)

14 (48)

43 (15)

None

5 (63)

1 (3)

0

1 (1)

0

0

7 (2)

Others

0

2 (6)

3 (5)

1 (1)

0

0

6 (2)

Participants’ responses to Q3 in the Global Symptom Survey, 6 h after gluten challenge, “What symptom/s overall have troubled you the most today, since having
the food challenge?” Please select a maximum of 3 symptoms: A. none, B. abdominal pain/cramps, C. vomiting, D. nausea, E. diarrhoea/loose stool, F. gas
(flatulence), G. bloating, H. tiredness, I. headache, J. others (please specify)
‡
The peak overall severity was the worst hourly descriptor rating reported by patients over 6 h after gluten challenge in the Global Symptom Survey for the question, “Overall, how
would you rate the severity of your digestive symptoms in the past 1 h? (e.g. feeling or being sick, abdominal pain or cramps, feeling bloated, having loose stools or passing gas)”
a
Percentage of patients for each severity subgroup, e.g. none and very mild
b
Percentage of all 295 patients

symptom severity and with peak serum IL-2 after gluten
challenge. None of the ten patient characteristics assessed
was significantly associated with clinical severity. In contrast, patient age and age at diagnosis were associated with
elevation in serum IL-2. In the subgroup of 52 patients described elsewhere who had quantitative histology performed on second part duodenal biopsies [14], patients
with villous atrophy (Fig. 3g), or increased intra-epithelial
lymphocyte (IEL) density, tended to have higher serum
IL-2 levels at 4 h after gluten (IELs > 25 per 100 epithelial
cells, n = 42, median 5.3 pg/ml, interquartile range 1.4–
12.8 vs IELs ≤ 25, n = 10: 0.9, < 0.5–6.5; p = 0.083 by
Mann-Whitney U test).
HLA-DQ genotype was associated with peak serum IL-2
concentration and the proportion of IL-2 responders, but
not clinical severity of gluten reactions (Table 4, Additional file 1: Table S6 and S7). The median peak serum
IL-2 concentration was more than seven times higher in
patients positive for HLA-DQ2.5 than those who were
negative (Table 4). Peak serum IL-2 concentrations were
also significantly higher in homozygotes for HLADQB1*02 than heterozygotes. In the group of patients
negative for HLA-DQ2.5, there were individuals positive
for HLA-DQ8, HLA-DQ2.2 or HLA-DQ7 alone who elevated serum IL-2 levels and were symptomatic after gluten
challenge (Additional file 1: Table S8). Most patients heterozygous for HLA-DQ8 who did not carry HLA-DQ2.2
or DQ7 did not elevate serum IL-2 after gluten. A very severe clinical reaction and strong serum IL-2 response was
observed in one patient who was positive for HLA-DQ7
and HLA-DQ6.

Second gluten challenge after 5 months

A group of 36 placebo-treated patients had a masked gluten during the treatment period of the RESET CeD Study
[6], which was between 20 and 22 weeks after their screening gluten challenge. Although the compositions of the
two gluten challenges were identical, the second gluten
challenge more often caused vomiting (16, 44% vs 8, 22%;
p = 0.047, Fisher exact test), and serum IL-2 levels at 4 h
were higher (median 10.1, 3.0–43 pg/ml vs 4.6, 1.3–17.8;
p = 0.0013 Wilcoxon signed rank test). Individual patients’
serum IL-2 levels at 4 h after the first and second challenges were, however, closely correlated (Fig. 3h), and all
but one patient who vomited after the first gluten challenge also vomited after the second (odds ratio [OR] 14.8;
p = 0.012, Fisher exact test). A more detailed symptom
analysis was not possible because patient-reported outcomes were assessed only after 1 day following the second
gluten challenge [6].

Discussion
This is the largest study to characterise symptoms and
cytokine release following acute gluten exposure in CD.
Due to its large sample and participant diversity, this
study provides novel insights into the relation between
gluten-mediated symptoms and immune activation, and
the influence of patient factors. For the first time, we
provide functional evidence for the influence of HLADQB*02 gene dose on in vivo immune activation after
oral gluten ingestion. We also provide functional data
supporting population studies that HLA-DQ7 should be
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Fig. 3 Serum IL-2 elevation in 295 patients over 6 h after gluten challenge. a Median and interquartile range of serum IL-2 concentrations at 2-h
intervals after gluten; significance tested by Wilcoxon matched-pairs signed rank test. b The frequency distribution of peak serum IL-2
concentrations in patients after gluten. c Median and interquartile range of serum IL-2 concentrations at 4 h and peak hourly numerical rating for
global severity of digestive symptoms (GloSS). d Median and interquartile range of serum IL-2 concentrations 4 h and peak hourly severity of
nausea. e Median and interquartile range of serum IL-2 concentrations at 4 h and whether patients experienced vomiting after gluten challenge. f
Mean and standard error of the mean of serum IL-2 concentrations after gluten according to gluten reaction severity (peak severity descriptor of
digestive symptoms rated each hour in the GloSS). g Peak serum IL-2 concentrations after gluten according to villous height to crypt depth ratio
(VH:CrD) in the second part duodenal biopsies indicating the presence of villous atrophy (VH:CrD ≤ 2) (n = 39 patients) or absence (n = 13). h
Paired serum IL-2 concentrations at 4 h after two separate food challenges with 6-g gluten protein. Data for 36 patients who received placebo
treatment during the RESET CeD Study and had both a screening (unmasked) and a second (masked) challenge 20 to 22 weeks later. The gluten
challenges used the same format administering the equivalent of 6-g gluten protein in 10-g vital wheat gluten mixed in water
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Table 4 HLA-DQ genotype and serum IL-2 after gluten
Genotype group†,
participants (n)

Serum IL-2 concentrations, median (interquartile range) pg/ml
2h

4h

6h

Maximum

1. DQ2.5 positive (266)

2.2 (< 0.5–8.6)

3.2 (0.6–10.7)

1.2 (< 0.5–4.5)

4.6 (0.8–13.1)

217 (82%)

‡‡

2. DQ2.5 negative

(29)

††

Responders‡
participants,
n (%)

< 0.5 (< 0.5–1.2)

0.6 (< 0.5–2.9)

< 0.5 (< 0.5–1.1)

0.6 (< 0.5–3.6)

17 (52%)

3. DQ2.5, 2.5 (34)

2.7 (0.8–8.0)

3.7 (1.3–9.4)

1.6 (0.6–4.9)

5.9 (1.8–10.8)

29 (85%)

4. DQ2.5, 2.2 (56)

5.5 (2.5–12.9)

9.0 (2.6–22.9)

3.7 (0.9–7.0)

10.2 (4.7–24.5)

52 (93%)

5. DQ2.5, 7 (15)

0.8 (< 0.5–7.4)

1.8 (< 0.5–5.0)

0.8 (< 0.5–1.4)

1.8 (< 0.5–9.0)

11 (73%)

6. DQ2.5, 8 (36)

1.1 (< 0.5–6.7)

2.4 (< 0.5–5.7)

0.9 (< 0.5–2.8)

2.7 (0.6–8.5)

28 (78%)

7. DQ2.5trans (18)

1.5 (0.7–8.2)

3.3 (0.9–12.5)

1.5 (0.6–6.9)

3.3 (0.9–12.5)

16 (89%)

8. DQ2.5cis, X (107)

1.4 (< 0.5–6.3)

1.9 (< 0.5–8.1)

0.8 (< 0.5–3.0)

2.5 (0.6–10.4)

81 (76%)

†

HLA-DQA and DQB alleles for the following genotype groups: 1. DQA1*05 and DQB1*02 both present; 2. absent either or both DQA1*05 and DQB1*02; 3;
homozygous both DQA1*05 and DQB1*02; 4. DQA1*02,05, and DQB1*02 homozygous; 5. DQA1*05 homozygous and DQB1*02,03; 6. DQA1*03,05 and DQB1*02,03; 7.
DQA1*02,05 and DQB1*02,03; 8. Other patients with DQA1*05 and DQB1*02
‡
Responders defined by maximum serum IL-2 concentration at least 0.5 pg/ml
††
Mann-Whitney test false discovery rate-adjusted p values for six comparisons were significant for the presence of DQ2.5 (group 1 vs 2), p = 0.004; DQB1*02 gene
dose (groups 5, 6, 7 and 8 vs 3 and 4), p = 0.0009; p values were not significant for DQA1*05 gene dose (groups 4, 6, 7 and 8 vs 3 and 5), DQ2.5 homozygotes vs
DQ2.5, 2.2 (group 3 vs 4), DQ2.5cis, X vs DQ2.5trans (group 7 vs 8) and for DQ2.5,8 vs DQ2.5cis, X (group 7 vs 8)
‡‡
See Table S8 for genotypes, symptoms and IL-2 responses of HLA-DQ2.5-negative patients

considered among genotypes conveying susceptibility to
CD [15, 16].
The present report replicates and greatly extends findings from our earlier studies involving smaller, more selected patient cohorts [6–8]. Here, we show that the
severity of individual digestive symptoms was strongly
correlated with one another and with elevations in serum
IL-2. The kinetics of serum IL-2 levels matched the changing severity of early digestive symptoms, especially nausea. Some symptoms in the CeD PRO including gas,
headache and tiredness were not correlated with serum
IL-2 levels and, therefore, may be more strongly influenced by non-gluten factors, such as a nocebo effect.
In this study, cytokine release was reproducible after successive gluten challenges, and responses were closely correlated for individual patients. Therefore, it is likely that in
patients with treated CD who inadvertently ingest gluten, the
small intestinal mucosa, the gut-associated lymphoid organs
and extra-intestinal organs are regularly exposed to elevated
concentrations of pro-inflammatory cytokines. Systemic
cytokine release after gluten may offer an explanation for
some of the extra-intestinal manifestations reported for CD.
Fever, hypotension and hypoxia are cardinal features of
the cytokine release syndromes associated with systemically administered agents [17], but these adverse events
were absent or rare after gluten. This study shows that a
single one-off gluten exposure transiently elevates serum
IL-2 levels to as high as 1000 pg/ml, which is higher than
the peak levels after the first dose of an anti-CD3 biologic
[18] or with CAR T cell immunotherapy [19].
This study had several limitations. Although the number
of patients enrolled in this study was more than eight times
larger and more diverse than in previous bolus gluten challenge studies [6–8], our findings may not be relevant to

children and adolescents, patients regularly consuming gluten or those without CD who strictly avoid gluten. In particular, participants in this study had volunteered for an
experimental immunotherapy trial and may not be representative of patients with CD in the communities where
they lived. A potentially significant limitation of this study
was also an important strength: the food challenge had a
standardised format with a fixed amount of gluten from a
single supplier and a confirmed low FODMAP content.
Findings may not be the same for different amounts of gluten administered in other formats. Our previous studies,
however, indicate that masked and unmasked food challenges with the same amount and format as the present
study result in comparable elevations in serum IL-2 [6, 7].
The gluten challenge dose is likely to be much higher than
the amount patients with CD following gluten-free diet
might be exposed to with accidental or inadvertent exposure. For logistical reasons, we measured a single cytokine in
serum to quantify immune activation after gluten. Other cytokines may be useful to complement IL-2, but data available at present do not clearly indicate which other cytokines
could serve this role [10]. The present study included all 36
patients reported separately following placebo food challenge in the treatment period of the RESET CeD Study [6].
The relative size and responsiveness of the glutenreactive CD4+ T cell population, and the level of antigenic
stimulation it receives, are an attractive explanation for the
severity of symptoms and peak levels of serum IL-2 after
gluten challenge [8]. Previously, we reported significant
correlations between peak IL-2 levels and the frequency of
tetramer-stained gluten-specific effector memory CD4+ T
cells in the blood [8]. Factors that were significantly associated with higher serum IL-2 elevation after gluten in the
current study included higher IL-2 response after a
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previous gluten challenge and HLA-DQ genotype being
positive for HLA-DQ2.5 and homozygous for HLADQB1*02. The data presented here is the first in vivo evidence supporting a HLA-DQ2.5 gene dose effect on the intensity of immune reactivation after patients ingest gluten.
CD participants who were HLA-DQ8 (without HLADQB1*02) had much lower IL-2 responses after gluten,
consistent with the weaker association between this genotype and CD [20, 21]. Future assessment of this uncommon
CD subgroup is warranted. Here, we also observed that
older patients and older patient age at diagnosis were associated with greater IL-2 elevations. Future studies including
children as well as older patients could address this intriguing observation.
The current study showed that gluten challenge with assessments of symptom severity and serum IL-2 may inform
the care of patients following a gluten-free diet. For example, in those on a gluten-free diet with an unclear diagnosis of CD, a positive IL-2 result would strongly support a
CD diagnosis whilst a negative IL-2 could identify those
who need a diagnostic re-evaluation of CD. In confirmed
CD, the degree of symptoms and IL-2 rise following a standardised challenge may help stratify the patients who would
benefit most from adjunctive pharmaceutical treatments
currently under development. Prospective validation to
define the clinical utility of this approach is warranted.

Conclusions
Most patients with treated CD experience a characteristic
cytokine and symptom response after acute oral gluten
challenge. Nausea and vomiting are hallmarks for moderate
or more severe cytokine release reactions after gluten. Bolus
gluten challenge with IL-2 assessments has the potential to
be integrated into clinical practice to evaluate the diagnosis
and management of patients on gluten-free diets.
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polyols; GloSS: Global Gastrointestinal Symptom Survey; HLA: Human
leukocyte antigen
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